VARIATION IN ANGIOTENSIN‐CONVERTING ENZYME (ACE) INHIBITOR AFFINITY AT TWO BINDING SITES ON RAT PULMONARY ACE: INFLUENCE ON BRADYKININ HYDROLYSIS

Clinical and Experimental Pharmacology and Physiology

Volumn 19, Issue 5, 1992, Pages 353-357

  Perich, Rose B ^a   Jackson, Bruce ^a   Johnston, Colin I ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

angiotensin converting enzyme; angiotensin converting enzyme inhibitor; binding sites; bradykinin; cilazaprilat; quinaprilat; radioligand.

Indexed keywords

9 [1 CARBOXY 3 (4 HYDROXYPHENYL)PROPYLAMINO] 10 OXOPERHYDROPYRIDAZINO[1,2 A][1,2]DIAZEPINE 1 CARBOXYLIC ACID; CILAZAPRILAT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IODINE 125; LISINOPRIL; QUINAPRILAT; UNCLASSIFIED DRUG;

ANIMAL TISSUE; CONFERENCE PAPER; DRUG PROTEIN BINDING; ENZYME MECHANISM; ISOTOPE LABELING; LUNG; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION; TESTIS;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMAL; BINDING SITES; BRADYKININ; HYDROLYSIS; IODINE RADIOISOTOPES; KINETICS; LUNG; MALE; PEPTIDYL-DIPEPTIDASE A; PYRIDAZINES; RADIOLIGAND ASSAY; RATS; RATS, INBRED STRAINS; STRUCTURE-ACTIVITY RELATIONSHIP; SUPPORT, NON-U.S. GOV'T; TESTIS; VARIATION (GENETICS);

EID: 0026534983     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.1992.tb00470.x     Document Type: Article

References (21)

1. Mouse angiotensin‐converting enzyme is a protein composed of two homologous domains
2. A deeply recessed active site in angiotensin‐converting enzyme is indicated from the binding characteristics of biotin‐spacer‐inhibitor reagents
3. Inhibition of rabbit lung angiotensin‐converting enzyme by Nα‐[(S)‐1‐carboxy‐3‐phenylpropyl]l‐alanyl‐l‐proline and Nα‐[(S)‐1‐carboxy‐3‐phenylpropyl]l‐lysyl‐L‐proline
4. Evidence for a single active site in the human angiotensin I‐converting enzyme from inhibitor binding studies with RU44403: Role of chloride
5. Simultaneous analysis of families of sigmoidal dose‐response curves: Application to bioassay, radioligand assay, and physiological dose‐response curves
6. Molecular cloning of human testicular angiotensin‐converting enzyme: The testis isozyme is identical to the C‐terminal half of endothelial angiotensin‐converting enzyme
7. Angiotensin‐converting enzyme: zinc–and inhibitor‐binding stoichiometrics of the somatic and testis isozymes
8. Molecular and catalytic properties of rabbit testicular dipeptidyl carboxypeptidase
9. A highly sensitive fluorometric assay for ‘enkephalinase’, a neutral metalloendopeptidase that releases tyrosine‐glycine‐glycine from enkephalins
10. 125I]‐MK351A binding studies of plasma and tissue ACE during variation of salt status in the rat
11. Hormonal responses to angiotensin blockade: Comparison between receptor antagonism and converting‐enzyme inhibition
12. Angiotensin‐converting enzyme inhibitors. Emerging differences and new compounds
13. Structure of testicular angiotensin‐converting enzyme. A segmental isozyme
14. LIGAND: A versatile computerized approach for the characterization of ligand binding systems
15. Angiotensin‐converting enzyme inhibitors act at two different binding sites on angiotensin‐converting enzyme
16. 2–and COOH‐terminal tripeptides from the luteinizing hormone‐releasing hormone
17. The broad substrate specificity of human angiotensin I‐converting enzyme
18. Two putative active centres in human angiotensin I‐converting enzyme revealed by molecular cloning
19. 3H] Captopril binding
20. The two homologous domains of human angiotensin I‐converting enzyme are both catalytically active
21. Expression and characterization of recombinant human angiotensin I‐converting enzyme. Evidence for a C‐terminal transmembrane anchor and for a proteolytic processing of the secreted recombinant and plasma enzymes